<DOC>
	<DOCNO>NCT01113437</DOCNO>
	<brief_summary>Hypothesis- Omalizumab ( humanize monoclonal anti-IgE antibody ) improve disease control reduce bronchial mucosal inflammation non-atopic asthma . In order test hypothesis , investigator propose placebo control , double blind , parallel group study obtain proof principle omalizumab exert beneficial effect disease control non-atopic severe adult asthmatic age 18-60 year . Forty patient randomize 1:1 ratio receive omalizumab match placebo . Following 12 week treatment omalizumab/placebo , treatment continue 8 week , anti-asthma treatment reduce . Dosages administer 4 2 weekly interval 16 week period ( 5 10 dos total ) , correspond time state necessary judge efficacy therapy accord omalizumab 's licensed indication atopic asthma . Efficacy judge clinical monitoring bronchial biopsy ass effect bronchial inflammation local IgE production .</brief_summary>
	<brief_title>Omalizumab Non-atopic Asthma</brief_title>
	<detailed_description>The primary aim study obtain proof principle omalizumab therapy maintain lung function , symptom control quality life group non-atopic , moderate/severe asthmatic whose regular anti-asthma therapy uniformise reduce 8 week period follow omalizumab/placebo therapy latter therapy continue . A secondary aim see whether omalizumab , compare placebo therapy reduce bronchial inflammation local IgE production bronchial mucosa group asthmatic . Clinical outcome measure The omalizumab placebo treat group compare change follow clinical outcome ( repeat measurement daily peak flow symptom mean value first last 10 day relevant study period compare ) . 1. prior reduction exist anti-asthma therapy ( first 12 week study ) : - Pre-bronchodilator FEV1 ( primary outcome measure ) - Morning even peak expiratory flow - Exhaled nitric oxide - Day night time symptom score - Total dosage rescue beta2-agonist - Total symptom free day - Validated asthma Quality Life score 2. anti-asthma therapy reduction phase ( subsequent 8 week study ) : - The primary outcome measure disease exacerbation , define need rescue oral corticosteroid medication worsen symptom and/or deterioration lung function , agree patient study physician - Secondary outcome measure include measurement list section ( ) , unless measure disease exacerbation ( primary outcome measure ) Laboratory outcome measure These arise immunological , immunohistochemical molecular analysis peripheral blood bronchial biopsy take patient begin end first 12 week study prior reduction anti-asthma therapy comprise change : - Lay collagen type I , III , IV V tenascin - Vascular structure angiogenic stimulus ( collagen type IV , CD31 human VEGF ( 29,30 ) - Inflammatory cell ( eosinophil , T cell , B cell , plasma cell , macrophage , neutrophil , mast cell ) - Goblet cell stain use monoclonal anti-Muc-5AC antibody - Immunoglobulin E high- low-affinity receptor stain use specific monoclonal antibody previous study . B cell ( CD20+ ) plasma cell ( CD138+ ) examine expression free kappa lambda IgE light chain use double , sequential IHC . Staining analysis : Entire area stain biopsy section subject image analysis use Zeiss Vision KS300 system allow objective , unbiased digital image analysis use powerful macro language . Cytokine chemokine concentration endobronchial tissue homogenate : These measure homogenate 2 biopsy electrochemiluminescence use SECTOR Imager 6000 assay kit produce Meso Scale Discovery . The MS6000 Human TH1/TH2 10-Plex Base Kit use measure IFN-gamma , IL-1beta , IL-2 , IL-4 , IL-5 , IL-10 , IL-12p70 , IL-13 , TNF-alpha . The MS6000 Human Chemokine 9-Plex Base Kit use measure Eotaxin , Eotaxin-3 , IL-8 , IP-10 , MCP-1 , MCP-4 , MDC , MIP-1beta , TARC . IgE synthesis : Two biopsy patient snap frozen RNA later subsequent analysis expression switch circle transcript IgE mature germline mRNA previous recent publication clone C-epsilon H-chain gene look evidence clonal expansion B cell cause B cell superantigens . Two biopsy \homogenised extraction B cell clone analysis IgE production antigen microarray . Serum : Stored serum sample take time bronchoscopy analyse complete antigen-specific IgE repertoire use microarray , anti-Fc-epsilon-RI activity use vitro basophil degranulation assay .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Inclusion criterion Males female age 18 60 year inclusive . Moderate severe nonatopic asthma define treat inhaled corticosteroid least 6 month . Daytime nighttime symptom least 3 day per week last 3 month prior screen visit ( despite take inhaled corticosteroid without beta2agonists leukotriene blocker . Prebronchodilator FEV1 4080 % predict ; reversibility equal 12 % response inhaled beta2agonists document time within past 2 year . Negative skin prick and/or vitro IgE test range 12 common aeroallergens ( pollen : grass , hazel , alder , birch ; dander : cat , dog ; dust mite : D.pteronyssinus , D.farinae ; mould : Cladosporium , Aspergillus , Alternaria ) . Exclusion Criteria Smoking within past year total smoking history 0.5 pack year . Pregnant lactating female risk pregnancy . Treatment 2000 mcg/day beclometasone , 1600 mcg/day budesonide 1000 mcg/day fluticasone inhalation regular systemic corticosteroid screening . Hospitalization asthma exacerbation require systemic corticosteroid therapy within 3 month screen visit . History life threaten asthma , define asthma episode require intubation and/or associate hypercapnia , respiratory arrest and/or hypoxic seizure . Patients , opinion study investigator , omalizumab therapy might normally require precaution ( history autoimmune disease , renal hepatic impairment , hyperimmunoglobulin E syndrome , allergic bronchopulmonary aspergillosis diabetes mellitus )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Bronchial Asthma</keyword>
	<keyword>Allergy</keyword>
</DOC>